Details of the Drug Combinations

General Information of This Drug (ID: DMMQ2OW)

• Drug Name: Nintedanib (DMMQ2OW)
• Synonyms: Nintedanib; Vargatef; 656247-17-5; BIBF-1120; Intedanib; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; G6HRD2P839; 1160294-26-7; CHEBI:85164; Nintedanib

Indication

Idiopathic pulmonary fibrosis; ICD 11: CB03.4; Status: Approved [1]; Non-small-cell lung cancer; ICD 11: 2C25.Y; Status: Approved [2]; Ovarian neoplasm; ICD 11: N.A.; Status: Approved [2]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 2 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

23 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-263 + Nintedanib	DCRTDYP	ABT-263	Ewing sarcoma (Cell Line: TC-71)	[4]
Doxorubicin + Nintedanib	DCC9CUP	Doxorubicin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
JQ1 + Nintedanib	DCPPAQK	JQ1	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Ruxolitinib	DCZMUVN	Ruxolitinib	T-cell leukemia/lymphoma (Cell Line: ED-40515)	[5]
Nintedanib + AT13387	DCXHPP2	AT13387	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Artemether	DCC0YLW	Artemether	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Panobinostat	DC9C9YS	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Nintedanib + Formononetin	DC3TKUI	Formononetin	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Steroid derivative 1	DC0ZE8H	Steroid derivative 1	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Mitomycin	DCGWK16	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Nintedanib + OSI-906	DCYUZ4D	OSI-906	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Pelitinib	DC5V5MN	Pelitinib	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Verteporfin	DC00JP2	Verteporfin	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Tivantinib	DCQTACG	Tivantinib	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + (-)-englerin A	DCHY1AH	(-)-englerin A	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Lestaurtinib	DCU9OEW	Lestaurtinib	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + MK-2206	DCWTMVU	MK-2206	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Ibrutinib	DC3796J	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Nintedanib + LY2874455	DC8537I	LY2874455	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + CP-868596	DCHOZO2	CP-868596	Ewing sarcoma (Cell Line: TC-71)	[5]
Nintedanib + Formononetin	DC5UYL6	Formononetin	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
Nintedanib + MK-2206	DCPUSE1	MK-2206	Hodgkin lymphoma (Cell Line: U-HO1)	[4]
PF-562271 + Nintedanib	DCJXHP0	PF-562271	Hodgkin lymphoma (Cell Line: U-HO1)	[5]

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + Nintedanib	DCLJ9PR	Docetaxel	Breast Cancer	[6]
Letrozole + Nintedanib	DC896SH	Letrozole	Breast Cancer	[7]
Nintedanib + Nintedanib	DC9XWDV	Nintedanib	Carcinoma, Hepatocellular	[8]
Pirfenidone + Nintedanib	DCTN4WO	Pirfenidone	Pulmonary Fibrosis	[9]
Nintedanib + Capecitabine	DCRCJCE	Capecitabine	Colorectal Neoplasms	[10]
Docetaxel + Nintedanib	DC2J3QA	Docetaxel	Carcinoma, Non-Small-Cell Lung	[11]
Sildenafil + Nintedanib	DCBV8KL	Sildenafil	Idiopathic Pulmonary Fibrosis	[12]
Pirfenidone + Nintedanib	DC7YVGZ	Pirfenidone	Idiopathic Pulmonary Fibrosis	[13]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
• [2] Nintedanib FDA Label
• [3] ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] ClinicalTrials.gov (NCT01658462) Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
• [7] ClinicalTrials.gov (NCT02619162) Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
• [8] ClinicalTrials.gov (NCT01594125) Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
• [9] ClinicalTrials.gov (NCT01417156) Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
• [10] ClinicalTrials.gov (NCT02780700) Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
• [11] ClinicalTrials.gov (NCT02231164) LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
• [12] ClinicalTrials.gov (NCT02802345) Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
• [13] ClinicalTrials.gov (NCT02606877) A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination